

*Please provide your CV of 1-2 pages in length including details of the following items. This will be posted on the conference website.

- **Full Name:** Byoung Chul Cho
- **Current Position & Affiliation:** Professor & Yonsei Cancer Center, Yonsei University College of Medicine
- **Country:** Republic of Korea

• **Educational Background:**

- 1990-1995 Yonsei University College of Science
Department of Biochemistry, Seoul, Korea
- 1995-1996 Exchange student (Honor student)
Department of Biochemistry, Oregon State University
USA: Research on dNTP biosynthesis at Dr. C.K.Mathews Laboratory
(Chairman of Department)
- 1995-2001 Yonsei University College of Medicine, Seoul, Korea
- 2000 Visiting student, Harvard Medical School (Brigham and Women's Hospital)
- 2006 Master, Department of Medicine, Yonsei University College of Medicine
- 2011 Doctor of Philosophy, Department of Medicine, Graduate School of Yonsei University (Doctoral dissertation: Apoptosis and growth inhibition by sprouty2 in non-small cell lung cancer)

• **Professional Experience:**

- 2002-2006 Resident in Internal Medicine, Severance Hospital Seoul, Korea
- 2006-2008 Clinical Fellow, Yonsei Cancer Center Seoul, Korea
- 2008-2009 Instructor, Division of Medical Oncology, Yonsei Cancer Center Seoul, Korea
- 2009-2014 Assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine Seoul, Korea

2013-2015	Adjunct Senior Scientist, Cancer Science Institute	Singapore
2013-	Associate Editor, Lung Cancer	
2014-2019	Associate professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine	Seoul, Korea
2016-	Joint Faculty Professor, Severance Biomedical Science Institute (SBSI) : 의생명과학부겸무교수	Seoul, Korea
2019-	Professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine	Seoul, Korea
2019-	Chief, Lung Cancer Center, Yonsei Cancer Center	Seoul, Korea
2021-	Director, Yonsei New Il Han Institute for Integrative Lung Cancer Research	Seoul, Korea
2023-	Scientific Editor, Cancer Discovery	

• **Professional Organizations:**

2005-	American Society for Clinical Oncology	
2006-	Korean Cancer Study Group (KCSG)	
2007-	Korean Association for Clinical Oncology	
2008-	Korean Association for the Study of Lung Cancer (Board of Publication, Journal of Lung Cancer)	
2009-	The Korean Society for Head & Neck Oncology	
2009-	International Association for the Study of Lung Cancer (IASLC)	
2010-	Active member of Lung Cancer and Head & Neck Cancer Committee of KCSG	
2017-	European Society for Medical Oncology (ESMO)	

2020- Society for Immunotherapy of Cancer (SITC)

• **Main Scientific Publications:**

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.

Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hirt S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. *Lancet Oncol.* 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, **Cho BC**. *J Clin Oncol.* 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2. PMID: 34339292 Free PMC article. Clinical Trial.

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, **Cho BC**. *Lancet Oncol.* 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. PMID: 31587882 Clinical Trial.

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.

Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, **Cho**

BC.Ann Oncol. 2021 Mar;32(3):395-403. doi: 10.1016/j.annonc.2020.11.020. Epub 2020 Dec 2.PMID: 33276076

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of *EGFR* Exon 20 Insertion-Driven NSCLC.

Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, **Cho BC**.Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15.PMID: 32414908

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.

Rizvi NA, **Cho BC**, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators.JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237.PMID: 32271377

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, **Cho BC**.J Clin Oncol. 2017 Aug 10;35(23):2613-2618. doi: 10.1200/JCO.2016.71.3701. Epub 2017 May 18.PMID: 28520527 Clinical Trial.